The determination of liver fibrosis showed stage F0 in 29, F1 in 39, 34 patients in F2 and F3 stage each and 21 patients in F4 or advanced fibrosis leading to cirrhosis. Our data showed the ...

F0 – no fibrosis F1 – mild fibrosis F2 – moderate fibrosis F3 – advanced fibrosis F4 – cirrhosis. People with advanced fibrosis or cirrhosis are at higher risk of developing a type of liver cancer ...

Akero Therapeutics has revealed preliminary topline week 96 outcomes from its Phase IIb SYMMETRY study of efruxifermin (EFX) in individuals with biopsy-confirmed compensated cirrhosis (F4), Child ...

Reported unprecedented, statistically significant reversal of compensated cirrhosis (F4) due to MASH after 96 weeks of treatment with efruxifermin (EFX) in Phase 2b SYMMETRY study -- -- Completed ...

Reported unprecedented, statistically significant reversal of compensated cirrhosis (F4) due to MASH after 96 weeks of treatment with efruxifermin (EFX) in Phase 2b SYMMETRY study -- -- Completed ...

Detailed price information for Akero Therapeutics Inc (AKRO-Q) from The Globe and Mail including charting and trades.

ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 trials in patients with non-cirrhotic (F2-F3) and compensated cirrhotic (F4) metabolic dysfunction-associated steatohepatitis (MASH) continue to ...

(MENAFN- GlobeNewsWire - Nasdaq) -- Reported unprecedented, statistically significant reversal of compensated cirrhosis (F4) due to MASH after 96 weeks of treatment with efruxifermin (EFX ...

Akero (NASDAQ:AKRO) shares soared Monday on encouraging data from a Phase 2b study of efruxifermin in the treatment of patients with compensated cirrhosis (F4) due to MASH, also known as metabolic ...

ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 trials in patients with non-cirrhotic (F2-F3) and compensated cirrhotic (F4) metabolic dysfunction-associated steatohepatitis (MASH) continue to ...